



PHARMACY COVERAGE GUIDELINES
SECTION: DRUGS

ORIGINAL EFFECTIVE DATE: 11/20/14
LAST REVIEW DATE: 11/15/18
LAST CRITERIA REVISION DATE: 11/16/17
ARCHIVE DATE:

SITAVIG® (acyclovir) buccal tablet

Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage Guideline must be read in its entirety to determine coverage eligibility, if any.

This Pharmacy Coverage Guideline provides information related to coverage determinations only and does not imply that a service or treatment is clinically appropriate or inappropriate. The provider and the member are responsible for all decisions regarding the appropriateness of care. Providers should provide BCBSAZ complete medical rationale when requesting any exceptions to these guidelines.

The section identified as "Description" defines or describes a service, procedure, medical device or drug and is in no way intended as a statement of medical necessity and/or coverage.

The section identified as "Criteria" defines criteria to determine whether a service, procedure, medical device or drug is considered medically necessary or experimental or investigational.

State or federal mandates, e.g., FEP program, may dictate that any drug, device or biological product approved by the U.S. Food and Drug Administration (FDA) may not be considered experimental or investigational and thus the drug, device or biological product may be assessed only on the basis of medical necessity.

Pharmacy Coverage Guidelines are subject to change as new information becomes available.

For purposes of this Pharmacy Coverage Guideline, the terms "experimental" and "investigational" are considered to be interchangeable.

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. All other trademarks and service marks contained in this guideline are the property of their respective owners, which are not affiliated with BCBSAZ.

This Pharmacy Coverage Guideline does not apply to FEP or other states' Blues Plans.

Information about medications that require precertification is available at www.azblue.com/pharmacy.

Some large (100+) benefit plan groups may customize certain benefits, including adding or deleting precertification requirements.

All applicable benefit plan provisions apply, e.g., waiting periods, limitations, exclusions, waivers and benefit maximums.

Precertification for medication(s) or product(s) indicated in this guideline requires completion of the request form in its entirety with the chart notes as documentation. All requested data must be provided. Once completed the form must be signed by the prescribing provider and faxed back to BCBSAZ Pharmacy Management at (602) 864-3126 or emailed to Pharmacyprecert@azblue.com. **Incomplete forms or forms without the chart notes will be returned.**

PHARMACY COVERAGE GUIDELINES
SECTION: DRUGS

ORIGINAL EFFECTIVE DATE: 11/20/14
LAST REVIEW DATE: 11/15/18
LAST CRITERIA REVISION DATE: 11/16/17
ARCHIVE DATE:

SITAVIG® (acyclovir) buccal tablet (cont.)

Criteria:

- **Criteria for initial therapy:** Sitavig (acyclovir) is considered *medically necessary* for individuals with medical record documentation of **ALL** of the following:
1. Individual is 18 years of age or older
 2. A confirmed diagnosis of recurrent herpes labialis (cold sore) in an immunocompetent individual
 3. Individual has failure, contraindication, or intolerance to **TWO** of the following preferred step therapy agents:
 - Preferred step therapy agents include:
 - Generic acyclovir (Zovirax)
 - Generic famciclovir (Famvir)
 - Generic valacyclovir (Valtrex)
 4. There are **NO** contraindications
 - Contraindications include:
 - Hypersensitivity to acyclovir, milk protein concentrate, or any other component of the product

Initial approval duration: Total of 4 tablets for 12 months

- **Criteria for continuation of coverage (renewal request):** Sitavig (acyclovir) is considered *medically necessary* and will be approved when **ALL** of the following criteria are met:
1. Individual's condition responded while on therapy
 - Response is defined as:
 - Reduced pain, burning, tingling, redness, and pruritus
 2. Individual has not developed any contraindications that may exclude continued use
 - Contraindications as listed in the criteria for initial therapy section

Renewal duration: Total of 4 tablets for 12 months

Description:

Sitavig (acyclovir) buccal tablet is indicated for the treatment of recurrent herpes labialis (cold sores) in immunocompetent adults. The safety and effectiveness of Sitavig (acyclovir) in pediatric patients have not been established. The ability of pediatric patients to comply with the application instructions has not been evaluated. Use in younger children is not recommended due to potential risk of choking. Use of Sitavig (acyclovir) resulted in reduction in the duration of symptoms by a half day.

Acyclovir is a synthetic purine nucleoside analogue active against herpes viruses.

SITAVIG® (acyclovir) buccal tablet (cont.)

Herpes simplex virus type 1 (HSV-1) and Herpes labialis

- HSV-1 is a member of the family of herpesviruses that includes not only HSV-1, but also HSV-2, cytomegalovirus (CMV), Epstein Barr virus, and human herpesviruses 6, 7, and 8
- The principal clinical manifestation of primary HSV-1 infection is gingivostomatitis, sometimes associated with pharyngitis
- HSV-1 causes vesicular lesions of the lips and oral mucosa known as herpes labialis or cold sores
- After primary infection, HSV lives in a latent state in ganglion neurons and can reactivate
- Reactivation of prior HSV-1 infection occurs in the trigeminal sensory ganglion
- Reactivation may lead to cutaneous, and more commonly, mucocutaneous disease, known as herpes labialis, which occurs along the vermilion border of the lip
- Cold sores are painful blisters that form on or near the lips and inside of the mouth caused by an infection with HSV-1, they are different from canker sores
 - Canker sores are painful red or white sores that can form in the mouth and on the tongue but they do not form blisters or scab over
- The majority of patients are aware of prodromal symptoms that herald the onset of a reactivation episode, symptoms include pain, burning, tingling, redness, and pruritus that precede vesicle formation
- The frequency and severity of reactivation is determined by many factors, including stress or any underlying immunodeficiency, such as HIV infection
- In the immunocompetent host, recurrent episodes are usually of shorter duration than the primary episode
 - The median time from onset of prodromal symptoms to healing of the lesion is approximately five days.
- The frequency and severity of recurrent infections are greater in the immunocompromised host, who is also at risk for disseminated HSV-1 infection to uncommon sites, such as the lungs or gastrointestinal tract
- Rapid initiation of antiviral therapy for patients with episodic HSV-1 and a well-defined prodrome may result in earlier healing of lesions, decreased pain, and a shorter duration
 - Choice of agents includes:
 - Acyclovir (200 or 400 mg five times daily)
 - Famciclovir (750 mg twice daily for one day or 1500 mg as a single dose)
 - Valacyclovir (2 g twice daily for one day)
- Chronic suppressive therapy decreases the number of recurrences of herpes labialis among patients with frequent (more than four episodes per year) recurrences of HSV



PHARMACY COVERAGE GUIDELINES
SECTION: DRUGS

ORIGINAL EFFECTIVE DATE: 11/20/14
LAST REVIEW DATE: 11/15/18
LAST CRITERIA REVISION DATE: 11/16/17
ARCHIVE DATE:

SITAVIG® (acyclovir) buccal tablet (cont.)

- Patients with multiple painful or disfiguring lesions who do not have an identifiable prodrome or patients who have recurrences associated with serious complications, such as recurrent aseptic meningitis, may also benefit from chronic suppressive therapy
-

Resources:

Sitavig. Package Insert. Reference ID 3292406. Revised by manufacturer 04/2013. Accessed 10-23-2014, 10-13-2015, 10-18-2016

UpToDate: Treatment of herpes simplex virus type 1 infection in immunocompetent patients. Current through Sep 2017. https://www.uptodate-com.mwu.idm.oclc.org/contents/treatment-of-herpes-simplex-virus-type-1-infection-in-immunocompetent-patients?source=search_result&search=cold%20sores&selectedTitle=1~150#H26

UpToDate: Clinical manifestations and diagnosis of herpes simplex virus type 1 infection. Current through Sep 2017. https://www.uptodate-com.mwu.idm.oclc.org/contents/clinical-manifestations-and-diagnosis-of-herpes-simplex-virus-type-1-infection?source=search_result&search=cold%20sores&selectedTitle=2~150



An Independent Licensee of the Blue Cross and Blue Shield Association

Fax completed prior authorization request form to 602-864-3126 or email to pharmacyprecert@azblue.com. Call 866-325-1794 to check the status of a request. All requested data must be provided. Incomplete forms or forms without the chart notes will be returned. Pharmacy Coverage Guidelines are available at www.azblue.com/pharmacy.

Pharmacy Prior Authorization Request Form

Do not copy for future use. Forms are updated frequently.

REQUIRED: Office notes, labs, and medical testing relevant to the request that show medical justification are required.

Member Information			
Member Name (first & last):	Date of Birth:	Gender:	BCBSAZ ID#:
Address:	City:	State:	Zip Code:

Prescribing Provider Information			
Provider Name (first & last):	Specialty:	NPI#:	DEA#:
Office Address:	City:	State:	Zip Code:
Office Contact:	Office Phone:	Office Fax:	

Dispensing Pharmacy Information		
Pharmacy Name:	Pharmacy Phone:	Pharmacy Fax:

Requested Medication Information			
Medication Name:	Strength:	Dosage Form:	
Directions for Use:	Quantity:	Refills:	Duration of Therapy/Use:

Check if requesting **brand** only Check if requesting **generic**

Check if requesting continuation of therapy (prior authorization approved by BCBSAZ expired)

Turn-Around Time For Review	
<input type="checkbox"/> Standard <input type="checkbox"/> Urgent. Sign here: _____	<input type="checkbox"/> Exigent (requires prescriber to include a written statement)

Clinical Information	
1. What is the diagnosis? Please specify below. ICD-10 Code: _____ Diagnosis Description: _____	
2. <input type="checkbox"/> Yes <input type="checkbox"/> No Was this medication started on a recent hospital discharge or emergency room visit?	
3. <input type="checkbox"/> Yes <input type="checkbox"/> No There is absence of ALL contraindications.	

4. What medication(s) has the individual tried and failed for this diagnosis? Please specify below.
Important note: Samples provided by the provider are not accepted as continuation of therapy or as an adequate trial and failure.

Medication Name, Strength, Frequency	Dates started and stopped or Approximate Duration	Describe response, reason for failure, or allergy

5. Are there any supporting labs or test results? Please specify below.

Date	Test	Value

Pharmacy Prior Authorization Request Form

6. Is there any additional information the prescribing provider feels is important to this review? Please specify below.
For example, explain the negative impact on medical condition, safety issue, reason formulary agent is not suitable to a specific medical condition, expected adverse clinical outcome from use of formulary agent, or reason different dosage form or dose is needed.

Signature affirms that information given on this form is true and accurate and reflects office notes

Prescribing Provider's Signature:	Date:
-----------------------------------	-------

Please note: Some medications may require completion of a drug-specific request form.

Incomplete forms or forms without the chart notes will be returned.

Office notes, labs, and medical testing relevant to the request that show medical justification are required.